Planmed explores full-field digital
This Finnish company (Hall B, #7142) is developing a full-field digital mammography system that it plans to offer as a retrofit to its installed base of Sophie screening units. Sophie Digital uses charge-coupled device (CCD) technology and a
This Finnish company (Hall B, #7142) is developing a full-field digital mammography system that it plans to offer as a retrofit to its installed base of Sophie screening units. Sophie Digital uses charge-coupled device (CCD) technology and a slot-scanning architecture, with resolution of 17 line pairs/mm and a field-of-view of 24 x 30 cm. Planmed hopes to start clinical trials of the system next year in preparation for a regulatory submission to the FDA.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
